title: A phase I-II study of bi-weekly paclitaxel as first-line treatment in metastatic breast cancer.
abstract: BACKGROUND
  Single-agent bi-weekly paclitaxel was studied as first-line metastatic treatment for breast cancer in a phase I-II trial.
  
  
  METHODS
  Thirty-eight women with metastatic breast cancer were enrolled. Thirty-seven are evaluable for toxicity, 35 for response.
  
  
  RESULTS
  The MTD was defined at 160 mg/m2 q two weeks with dose limiting toxicity in two patients consisting of hematological toxicity (1) and neurotoxicity (2). Twenty patients were treated at 150 mg/m2, the recommended dose. Response rates were two CRs and nine PRs (overall 61%) at the RD of 150 mg/m2 and three CRs and 11 PRs for an overall RR of 67% for the two top doses.
  
  
  CONCLUSIONS
  The good drug tolerance, response rates, and convenience over weekly treatment suggest this may be a worthwhile regimen.
authors.affiliation: British Columbia Cancer Agency, Vancouver Centre, Canada.
authors.forename: K A
authors.initials: KA
authors.lastname: Gelmon
authors.forename: A
authors.initials: A
authors.lastname: Tolcher
authors.forename: S
authors.initials: S
authors.lastname: O'Reilly
authors.forename: C
authors.initials: C
authors.lastname: Campbell
authors.forename: C
authors.initials: C
authors.lastname: Bryce
authors.forename: T
authors.initials: T
authors.lastname: Shenkier
authors.forename: J
authors.initials: J
authors.lastname: Ragaz
authors.forename: D
authors.initials: D
authors.lastname: Ayers
authors.forename: L
authors.initials: L
authors.lastname: Nakashima
authors.forename: S
authors.initials: S
authors.lastname: Rielly
authors.forename: H
authors.initials: H
authors.lastname: Dulude
mesh_terms: D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D017239:Paclitaxel / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel